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Abstract
Tuberculosis (TB) remains a worldwide problem and the need for new drugs is increasingly
more urgent with the emergence of multidrug- and extensively-drug resistant TB. Inosine 5’-
monophosphate dehydrogenase 2 (IMPDH2) fromMycobacterium tuberculosis (Mtb) is an
attractive drug target. The enzyme catalyzes the conversion of inosine 5’-monophosphate
into xanthosine 5’-monophosphate with the concomitant reduction of NAD+ to NADH. This
reaction controls flux into the guanine nucleotide pool. We report seventeen selective
IMPDH inhibitors with antitubercular activity. The crystal structures of a deletion mutant of
MtbIMPDH2 in the apo form and in complex with the product XMP and substrate NAD+ are
determined. We also report the structures of complexes with IMP and three structurally dis-
tinct inhibitors, including two with antitubercular activity. These structures will greatly facili-
tate the development ofMtbIMPDH2-targeted antibiotics.
Introduction
Tuberculosis (TB) is a pandemic contagious infectious disease affecting nearly two billion peo-
ple worldwide, with 5.7 million new cases reported in 2013 according to theWorld Health Orga-
nization [1]. The currently approved standard first-line treatment is long and requires
combination therapy consisting of several antibiotics [2].Mycobacterium tuberculosis (Mtb), the
causative agent of most TB cases is a slow growing, remarkably successful pathogen capable of
switching between different physiological states and adapting to disparate host environments
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[3,4]. TheMtb pathogen can persist in a quiescent state and survive for decades as a latent infec-
tion [5,6]. The increased prevalence of multidrug resistant (MDR) and extensively drug resistant
(XDR) strains ofMtb, for which treatment options are very limited, demands the development
of more effective antitubercular agents, ideally with novel mechanisms of action [6,7].
The design of antimetabolites that inhibit biosynthesis of essential metabolites within a cell
is a classic approach for discovery of new antibiotics and chemotherapeutic agents. Indeed, one
of the first reported TB drugs, para-aminosalicylic acid, was recently shown to disrupt folate
biosynthesis [8], while the newest TB drug, bedaquiline exerts its activity through inhibition of
ATP synthesis [9]. Inosine 5’-monophosphate dehydrogenase (IMPDH) lies at a key intersec-
tion of the purine biosynthesis pathway and represents an extremely attractive target since it
controls flux of the guanine nucleotide pool. In many pathogens, guanine nucleotide levels are
IMPDH-dependent and thus inhibition of IMPDH is a viable strategy for design of new che-
motherapeutic agents [10]. The purine nucleotide biosynthetic pathway ofMtb, in common
with other bacteria, contains three different enzymes from that of humans [11,12]: (1)Mtb
contains both the folate dependent N1-(5-phospho-D-ribosyl)glycinamide (GAR) transformy-
lase (PurN) and the formate/ATP utilizing formyl- N1-(5-phospho-D-ribosyl)glycinamide
(FGAR) synthetase (PurT), whereas humans only contain GAR transformylase. (2) Humans
use a type I 2-(formamido)-N1-(5-phospho-β-D-ribosyl)acetamidine (FAGM) synthetase
composed only of PurL. Bacteria typically contain a type II FGAM synthetase, which is a com-
plex of PurLQS. Orthologs for both PurL and PurQ have been identified inMtb, as has a candi-
date PurS, which suggests thatMtb also utilizes the type II enzyme [11]. (3) Whereas humans
convert 5-amino-1-(5-phospho-D- ribosyl)imidazole (AIR) directly to 5-amino-1-(5-phos-
pho-D-ribosyl)imidazole-4-carboxylate (CAIR) via a class II AIR carboxylase (PurE class II),
Mtb uses N5-carboxyaminoimidazole ribonucleotide (NCAIR) synthetase (PurK) to first con-
vert AIR to NCAIR, then a class I AIR carboxylase converts NCAIR to CAIR. The remaining
steps are common to both humans andMtb. IMPDH catalyzes the NAD+-dependent conver-
sion of inosine 5’-monophosphate (IMP) to xanthosine 5’-monophosphate (XMP), the first of
the two step biosynthesis of guanosine 5’-monophosphate (GMP). GMP synthetase catalyzes
the conversion of XMP to GMP in a reaction that also hydrolyzes glutamine to glutamate and
ATP to AMP and pyrophosphate.
TheMtbH37Rv genome contains three genes with sequence similarity to bacterial IMPDH
(guaB1, guaB2, and guaB3); the functions of guaB1 and guaB3 are poorly understood and only
guaB2 was shown to encode an active IMPDH [13],[14] (S1 Fig [54, 55]). Consistent with this
finding, the guaB2 gene is essential and cannot be rescued by the other orthologs [15]. The
IMPDH activity of the guaB2 gene product,MtbIMPDH2, has been confirmed [14,16] and
small molecule inhibitors have also been described [14,16,17].
The enzymatic mechanism of IMPDH has been extensively studied and consists two steps, a
dehydrogenase and a hydrolase reaction (Fig 1A) [10,18]. Upon binding of IMP and NAD+
cofactor, a thioimidate enzyme-substrate adduct, E-XMP, is formed via a covalent bond to the
catalytic C341 (MtbIMPDH2 numbering) with concurrent production of NADH. Hydride
transfer occurs to the pro-S position with the cofactor in the anti-conformation (Fig 1B). The
cofactor is released and an active site mobile flap moves into the NAD+ site and facilitates
E-XMP hydrolysis with a conserved R443 acting as a general base. Thus, the enzyme has two
distinct conformations, an open form for the dehydrogenase reaction and a closed form for
E-XMP hydrolysis. IMPDH has multiple active site states (apoE, E•IMP, E•IMP•NAD+,
E-XMP•NADH adduct) that can be targeted for inhibitor design, and both the IMP/XMP and
cofactor binding sites have been exploited for that purpose [10,18,19].
Human and bacterial IMPDHs differ in their affinity toward the NAD+ cofactor. While the
nicotinamide portion of NAD+ binds similarly in human and Vibrio cholerae IMPDHs to
M. tuberculosis IMP Dehydrogenase Inhibitors
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preserve the interaction with IMP for hydride transfer, the interactions of the adenosine moiety
vary dramatically. In the human type II enzyme (hIMPDH2), the adenine ring π/π stacks
between a pair of aromatic residues within the same monomer as the IMP binding site (H253
and F282 in hIMPDH2; referred to as the AE-subsite; S1 Fig) and the cofactor maintains the
extended conformation typically found in dehydrogenases [20]. In contrast, in V. cholera
IMPDH (VcIMPDH), the adenine ring binds to the adjacent monomer and interacts with a dif-
ferent set of residues (referred to as the AB-subsite; S1 Fig) and the cofactor assumes a rare
compact conformation [21]. It also appears that adenine binding to this site is less constrained
because two different conformations are observed for this moiety in two crystal structures of
VcIMPDH[21]. This provides critical information that the design of bacteria-selective
Fig 1. Mechanism and inhibitors ofMtbIMPDH2. (A) Reactions catalyzed by IMPDH.MtbIMPDH2 numbering is shown. (B) The anti- and syn-
conformations of nicotinamide ring in NADH. (C) CpIMPDH inhibitors, for which crystal structures ofMtbIMPDH2•IMP•I were obtained. Portions of inhibitors
that bind in the nicotinamide-subsite (left side) and the AB-subsite (right side) are indicated. Stereochemistry is denoted where applicable. NAD+ is shown for
comparison.
doi:10.1371/journal.pone.0138976.g001
M. tuberculosis IMP Dehydrogenase Inhibitors
PLOS ONE | DOI:10.1371/journal.pone.0138976 October 6, 2015 3 / 21
inhibitors should focus on the AB-subsite. Importantly, compounds that bind with high affinity
to this site should not bind to human IMPDHs.
Bacterial IMPDH-specific compounds were discovered in a high throughput screen for
inhibitors of Cryptosporidum parvum IMPDH (CpIMPDH). Although C. parvum is a protozoa,
its IMPDH is a bacterial-like IMPDH [22]. Multiple potent chemotypes have been developed
as inhibitors of this enzyme (designated as classes A, C, D, N, P, and Q, among others) [23–
29]. These inhibitors target the AB-subsite and thus show high selectivity for bacterial
IMPDHs. Moreover, structural studies of CpIMPDH with representatives from two classes,
C64 andQ21, identified an “inhibitor minimal structural motif” (IMSM) consisting of A165
and Y358’ (prime denotes a residue from the adjacent monomer) that is required for com-
pound binding [27,30–32]. Bacterial IMPDHs have high sequence similarities and the IMSM
motif is found in many species, includingMtbIMPDH2 with A285/Y487’ in the corresponding
positions. However, despite this sequence conservation, the structure–activity relationships
(SAR) of a given inhibitor chemotype are not preserved between different bacterial IMPDHs,
thus structure-based compound optimization toward a given IMPDH cannot be performed by
simple knowledge-based prediction, but requires experimental verification [21,31,32].
Numerous efforts by several groups in academia and industry directed at characterization of
either apo or ligand-boundMtbIMPDH2 structures have been unsuccessful, likely due to the
very low solubility of the recombinantMtbIMPDH2 protein expressed in E. coli. We have over-
come this major limitation by designing a variant that lacks the non-catalytic CBS subdomain
(MtbIMPDH2ΔCBS), greatly improving solubility [21] without impacting enzyme catalytic
properties. Here we present the first crystal structures ofMtbIMPDH2ΔCBS, including the
apoenzyme, the E•XMP•NAD+ complex, and complexes with IMP and three inhibitors,
MAD1, P41, and Q67 (Fig 1C). In addition, we report the SAR forMtbIMPDH2ΔCBS inhibi-
tion along with antibacterial activity of several inhibitors from structurally distinct classes.
Results
Engineering IMPDH for inhibitor and structural studies
Deletion of IMPDH CBS domains facilitated crystallization of enzymes from several other
organisms [21], therefore we constructed a variant ofMtbIMPDH2 wherein residues
E126-R252 were replaced with a GG linker. TheMtbIMPDH2ΔCBS showed significantly
improved solubility and crystallizability properties[21] with the steady state kinetic parameters
comparable to those reported for the wild type enzyme (Table 1 [16]). Similar results were
reported recently for deletion mutants of three other bacterial IMPDHs [21]. Notably, the val-
ues of Km for both IMP and NAD
+ forMtbIMPDH2 are significantly higher than those of the
human enzymes, illustrating the functional differences between bacterial and human IMPDHs
(Table 1 [33–36]).
Antitubercular activity of CpIMPDH inhibitors
We tested 139 compounds developed in our CpIMPDH inhibitor program for antitubercular
activity [21,24,25,27–30,32,37,38], including compounds from the A benzotriazole (21), C
benzimidazole (9),D phthalazinone (19), P urea (52) and Q benzoxazole (37) structural series
(S1–S7 Tables). Most of these compounds were expected to be potent inhibitors of
MtbIMPDH2 based on their behavior versus CpIMPDH and Bacillus anthracis IMPDH
(BaIMPDH; S1–S8 Tables).
Five P compounds and twelveQ compounds displayed significant activity againstMtb
strain H37Rv in minimal BSA-free medium (MIC20 μM, Fig 2, Tables 2 and 3). The com-
pounds were somewhat less effective in BSA-supplemented rich media (Table 2). No active
M. tuberculosis IMP Dehydrogenase Inhibitors
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compounds were identified in the other structural series. The active compounds have signifi-
cantly more polar surface area (average topological polar surface area (tPSA) 83 ± 18 Å2) than
the inactive compounds (average tPSA = 64 ± 4 Å2, p< 0.001). The active and inactive com-
pounds have similar hydrophobicity (average cLogP = 4.1 ± 0.8 for the active versus
cLogP = 4.4 ± 1.3 for the inactive). All of the active compounds were potent inhibitors of
MtbIMPDH2ΔCBS, with values of Ki,app ranging from 13–2000 nM (Table 2). Notably, P67
andQ67 are the most potent inhibitors ofMtbIMPDH reported to date.
Several observations suggest that antitubercular activity results from inhibition of
MtbIMPDH2. First, (S)-isomers of theQ compounds inhibit bacterial IMPDHs, while the (R)-
isomers are inactive [27]. The racemate Q60 has approximately half the antitubercular activity
as the (S)-isomerQ67, as expected ifMtbIMPDH2 is the target (S7 Table). The values of MIC
for ten active compounds, including all the P compounds, increased by at least a factor of 4 in
the presence of guanine. This rescue provides strong evidence for the on-target activity of the
compounds due to inhibition ofMtbIMPDH2 in the bacteria. The values of MIC increased by
lesser extents for the remaining compounds (Q9,Q22,Q27,Q42,Q46,Q49,Q59). These com-
pounds may also engage another target. Lastly, antitubercular activity correlated roughly with
the potency ofMtbIMPDH2ΔCBS inhibition (Table 2 and S3 Fig).
All five P compounds also displayed antibacterial activity against B. anthracis (S8 Table
[37]). Of the eightQ compounds also tested against B. anthracis, onlyQ67 displayed activity
against both bacteria. While P32 and Q67 have similar activity against both bacteria, P41 and
P67 are 5-7-fold more effective againstMtb and P146 and P150 are 15-28-fold more effective
against B. anthracis. Differences in the SARs for enzyme inhibition cannot simply account for
these differences in antibacterial activity (S8 Table and S2 Fig). Therefore, differences in cellu-
lar accumulation likely determine antibacterial spectrum. Interestingly, the compounds active
Table 1. MtbIMPDH2ΔCBS kinetic parameters.
MtbIMPDH2ΔCBS MtbIMPDH2a hIMPDH1 hIMPDH2
Km (IMP), μM 41 ± 4 78 ± 6 14–18b,c,d 4–9b,c,e
Km (NAD+), μM 580 ± 30 1005 ± 95 42–70b,c,d 6–32b,c,e
Kii (NAD+), mM 16 ± 1 5.0 ± 0.6 2.0 ± 0.6d 0.59 ± 0.02e
kcat, s–1 0.57 ± 0.01 0.53 ± 0.03 1.2–1.8b,c,d 0.4–1.4b,c,e
aReference [16]
bReference [33]
cReference [34]
dReference [35]
eReference [36]
doi:10.1371/journal.pone.0138976.t001
Fig 2. General structures of CpIMPDH inhibitors from P and Q series.Modular structure of (A) P compounds and (B) Q compounds. Substituents X, Y,
R1 and R2 are listed in Table 3. Designation “5” and “6” refers to the position in the benzoxazole ring of Q compounds.
doi:10.1371/journal.pone.0138976.g002
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Table 2. Antitubercular activity ofCpIMPDH inhibitors. The values of Ki,app for inhibition ofMtbIMPDH2ΔCBS.
Cmpd Ki,app a (nM) cLogP tPSA (Å2) MIC in GAST media MIC in 7H9 media
- Gua + Gua - Gua + Gua
MIC (μM) N MIC (μM) N MIC (μM) N MIC (μM) N
P32 158 b 2.4 116.8 11.4 ± 5.3 4 40 3 27.2 ± 15.7 4 38 3
P41 17 ± 4 4.56 61.4 5.0 ± 3.1 4 40 3 33.3 ± 13.5 4 38 3
P67 13 ± 5 3.34 94.0 2.9 ± 0.4 3 40 3 15.7 ± 5.5 3 19 ± 6 3
P146 37 ±8 3.53 103.3 14.9 ± 10.0 2 >50 1 28.0 ± 9.0 2 44 ± 7 2
P150 35 ± 3 4.42 94.03 14.2 ± 5.0 2 >50 1 43.5 ± 6.0 2 63 ± 13 2
Q9 650 ± 140 3.59 72.3 17.5 ± 7.0 2 50 1 28.0 ± 19.2 3 37 2
Q22 2000 ± 60 c 5.18 72.3 19.8 ± 14.9 3 25 ± 12 2 25.3 ± 8.3 4 50 ± 40 3
Q27 240 ± 40 4.21 72.3 15.2 ± 8.2 4 38 ±12 3 19.1 ± 13.3 4 60 ± 40 3
Q33 150 ± 50 3.68 81.5 5.3 ± 0.9 3 24 ± 16 3 10.4 ± 1.8 3 21 ± 4 3
Q36 76 ± 27 c 4.85 72.3 9.4 ± 3.0 2 37 1 15.8 ± 5.5 3 28 ± 9 2
Q42 620 ± 70 2.97 90.7 17.3 ± 4.1 5 41 ± 6 4 22.0 ± 9.1 5 31 ± 7 4
Q46 130 ± 40 4.01 124.1 11.6 ± 5.7 4 38 ± 12 3 19.5 ± 4.1 4 44 ± 7 2
Q49 440 ± 40 3.61 63.1 12.7 ± 5.3 3 31 ± 19 2 21.1 ± 11.6 4 31 ± 6 3
Q59 40 ± 7 4.85 72.3 9.7 ± 4.1 4 26 ± 12 3 9.1 ± 3.1 4 25 ± 20 3
Q60 40 ± 16 5.02 75.1 14.5 ± 4.0 2 >50 1 14.5 ± 4.8 3 19 ± 0 2
Q67 14 ± 3 5.02 75.1 6.7 ± 3.0 2 50 1 11.8 ± 6.3 3 35 ± 15 2
Q77 100 ± 20 4.21 72.3 6.3 ± 3.0 2 37 1 11.0 ± 2.0 2 19 ± 0 2
MAD1 1580 ± 70 d 1.57 209 100 e 1 >100 e 1 50 1 75 1
a. Average and standard deviation of three independent determinations unless otherwise noted.
b. n = 1.
c. n = 2.
d. Ki,app of 1500 nM was determined for inhibition of wild-type MtbIMPDH2 reported in [16]
e. MIC determined after two weeks.
doi:10.1371/journal.pone.0138976.t002
Table 3. Structures of CpIMPDH inhibitors with antitubercular activity.
P compound Q compound
Cmpd X Y Cmpd R1 X Y Connection R2
P32 NOH NH2 Q9 Ph O CH3 5 4-Py
P41 CH2 N(CH3)2 Q22 2,4-di-ClPh O CH3 5 2-Py
P67 NOH N(CH3)2 Q27 2-ClPh O CH3 5 4-Py
P146 NOH 4-morpholinyl Q33 4-OCH3Ph O CH3 5 4-Py
P150 NOH N(CH2CH3)2 Q36 2,3-di-ClPh O (S)-CH3 5 4-Py
Q42 2,3-di-OCH3Ph O (S)-CH3 5 4-Py
Q46 2-Cl,3-NO2Ph O (S)-CH3 5 4-Py
Q49 Ph (S)-CH3 5 4-Py
Q59 2,3-di-ClPh O (S)-CH3 6 4-Py
Q60 2,3-di-ClPh NH CH3 5 4-Py
Q67 2,3-di-ClPh NH (S)-CH3 5 4-Py
Q77 2-ClPh O (S)-CH3 5 4-Py
doi:10.1371/journal.pone.0138976.t003
M. tuberculosis IMP Dehydrogenase Inhibitors
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against B. anthracis are significantly less hydrophobic than those active againstMtb
(cLogP = 3.5 ± 0.5, p = 0.018; S8 Table [37]).
The five active P compounds contain a 3-carboxamido-4-chlorophenyl ring. Remarkably,
the 4-chloro substituent is also found in 21 inactive P compounds, suggesting that the 3-car-
boxamido-4-chlorophenyl ring is critical for antitubercular activity. The 3-piperazinylcarbo-
nyl-4-chloro analog P94 is inactive, suggesting that the positive charge is deleterious (S5
Table). The inactive compounds include the alkene analog of P32 (P16), the ketone analog of
P32 (P25) and methyloxime analog of P67 (P74). P16, P25 and P74 are also expected to be
good inhibitors ofMtbIMPDH2, which suggests that the oxime group confers an advantage for
cellular accumulation.
All of the activeQ compounds exceptQ22 contain the 2-(pyrid-4-yl)benzoxazole group,
which largely reflects the SAR of enzyme inhibition for CpIMPDH and the consequential pre-
dominance of this group in theQ pool (70%). Nine of the activeQ compounds contain a
2-chloro-substituted phenyl ring, and five of these are 2,3-dichloro substituted.Q58 andQ64
are the only two inactive compounds that contain 2,3-dichlorophenyl group. Q58 is the 2-
(thiazol-2-yl)benzoxazole analog of the active compound Q36, whileQ64 is the 2-(thiazol-
5-yl)benzoxazole analog of the active compoundQ59. These substitutions are expected to
decrease the potency of enzyme inhibition by a factor of 4–20 based on CpIMPDH and
BaIMPDH data (S8 Table). Therefore the 2,3-dichlorophenyl group is important for antituber-
cular activity in the benzoxazole scaffold.
Mechanism ofMtbIMPDH2ΔCBS inhibition
Although the CpIMPDH inhibitors all bind in the cofactor site, their mechanisms of inhibition
can vary depending on their relative affinities for the E•IMP and E-XMP complexes. There-
fore we determined the mechanism of inhibition for the representative antitubercular com-
pounds P41 and Q67, as well as for compoundMAD1, the first reported inhibitor of
MtbIMPDH2 [16] (Fig 1C);.MAD1 is a third generation mycophenolic adenine nucleotide
(MAD) inhibitor [16,39,40] that bears the closest resemblance to NAD+ (Fig 1). All three com-
pounds are uncompetitive inhibitors with respect to IMP as expected, implying interactions
with the base of IMP are critical for binding (S9 Table). The mechanism of inhibition with
respect to NAD+ varies among the three compounds (S9 Table).MAD1 is an uncompetitive
inhibitor, suggesting that this compound has a strong preference for the E-XMP intermediate.
P41 is a noncompetitive inhibitor, indicating this compound has similar affinity to both
E•IMP and E-XMP.Q67 is a competitive inhibitor versus NAD+, suggesting that it has a
strong preference for E•IMP.
Overall structure
Five high resolution crystal structures were obtained forMtbIMPDH2ΔCBS (Table 4). These
include the apo form, the XMP•NAD+ complex, and three IMP•inhibitor complexes
(E•IMP•I) withMAD1, P41, andQ67. The structure of the tertiary complex of
MtbIMPDH2ΔCBS with XMP and NAD+ was obtained by soaking crystals containing the
MtbIMPDH2ΔCBS•IMP complex with 200 mMNAD+. Structures of protein-inhibitor com-
plexes were obtained by co-crystallization with IMP and inhibitor. In all five structures, the
first 26 or 27 N-terminal residues are disordered in every protein chain. An approximately
20-residue portion of the active site flap is also disordered, as observed for the majority of the
IMPDH structures reported to date.
M. tuberculosis IMP Dehydrogenase Inhibitors
PLOS ONE | DOI:10.1371/journal.pone.0138976 October 6, 2015 7 / 21
T
ab
le
4.
D
at
a
co
lle
ct
io
n
an
d
re
fin
em
en
ts
ta
ti
st
ic
s.
M
tb
IM
P
D
H
2Δ
C
B
S
M
tb
IM
P
D
H
2Δ
C
B
S
•I
M
P
•M
A
D
1
M
tb
IM
P
D
H
2Δ
C
B
S
•I
M
P
•P
41
M
tb
IM
P
D
H
2Δ
C
B
S
•I
M
P
•Q
67
M
tb
IM
P
D
H
2Δ
C
B
S
•I
M
P
•N
A
D
+
D
at
a
co
lle
ct
io
n
S
pa
ce
gr
ou
p
P
1
I4
I4
I4
I4
C
el
ld
im
en
si
on
s
a,
b,
c
(Å
)
75
.2
2,
75
.2
3,
75
.2
8
88
.2
3,
88
.2
3,
84
.6
3
87
.9
4,
87
.9
4,
84
.7
6
88
.2
5,
88
.2
5,
84
.2
7
88
.1
5,
88
.1
5,
85
.5
1
α
,β
,γ
(°
)
10
8.
3,
10
8.
3,
11
1.
9
P
ro
te
in
m
ol
ec
ul
es
/
A
S
U
4
1
1
1
1
T
em
pe
ra
tu
re
(K
)
10
0
10
0
10
0
10
0
10
0
R
ad
ia
tio
n
so
ur
ce
A
P
S
,1
9-
ID
A
P
S
,1
9-
ID
A
P
S
,1
9-
ID
A
P
S
,1
9-
ID
A
P
S
,1
9-
ID
W
av
el
en
gt
h
(Å
)
0.
97
91
8
0.
97
89
9
0.
97
89
9
0.
97
89
9
0.
97
91
8
R
es
ol
ut
io
n
(Å
)a
35
.7
3–
1.
70
(1
.7
3–
1.
70
)
35
.7
6–
1.
90
(1
.9
3–
1.
90
)
35
.6
7–
2.
00
(2
.0
3–
2.
00
)
30
.4
7–
1.
76
(1
.7
9–
1.
76
)
35
.8
0–
1.
60
(1
.6
3–
1.
60
)
U
ni
qu
e
re
ﬂ
ec
tio
ns
12
93
46
(3
62
8)
24
20
4
(7
79
)
21
40
7
(9
38
)
31
90
6
(1
55
5)
42
70
8
(1
97
5)
R
m
e
rg
e
b
0.
05
6
(0
.3
30
)
0.
10
5
(0
.3
26
)
0.
13
0
(0
.7
62
)
0.
08
9
(0
.6
44
)
0.
07
5
(0
.8
05
)
hIi
/hσ
Ii
17
.2
(2
.6
)
11
.7
(2
.1
)
8.
2(
1.
8)
10
.6
(2
.0
)
29
.0
(1
.8
1)
C
om
pl
et
en
es
s
(%
)
91
.4
(5
1.
5)
94
.5
(6
1.
0)
98
.0
(8
6.
1)
99
.7
(9
7.
5)
99
.5
(9
3.
1)
R
ed
un
da
nc
y
2.
2
(1
.8
)
4.
2
(2
.5
)
3.
9
(2
.1
)
4.
4
(2
.7
)
5.
8
(4
.0
)
R
eﬁ
ne
m
en
t
R
es
ol
ut
io
n
(Å
)
a
35
.7
3–
1.
70
(1
.7
1–
1.
70
)
35
.7
6–
1.
90
(1
.9
6–
1.
90
)
35
.6
7–
2.
00
(2
.0
9–
2.
00
)
30
.4
7–
1.
76
(1
.8
1–
1.
76
)
35
.8
0–
1.
60
(1
.6
4–
1.
60
)
R
eﬂ
ec
tio
ns
:w
or
k/
te
st
se
ta
12
28
67
/6
43
2
(2
09
7/
10
7)
23
81
1/
12
72
(2
10
3/
11
7)
20
30
0/
10
90
(2
21
9/
10
9)
30
28
2/
16
19
(2
43
7/
13
0)
40
39
4/
21
85
(2
34
3/
10
3)
R
w
o
rk
/R
fr
e
e
c,
a
0.
15
1/
0.
18
3
(0
.2
42
/0
.2
69
)
0.
14
3/
0.
18
9
(0
.2
19
/0
.2
86
)
0.
17
8/
0.
22
1
(0
.2
82
/0
.3
38
)
0.
15
3/
0.
17
9
(0
.2
39
/0
.2
50
)
0.
16
0/
0.
19
1
(0
.2
31
/0
.2
86
)
N
o.
of
at
om
s:
pr
ot
ei
n/
lig
an
ds
d
/
w
at
er
11
79
3/
17
0/
79
3
25
85
/8
4/
16
9
25
27
/5
1/
11
8
26
40
/6
4/
18
8
23
86
/6
8/
16
1
A
ve
ra
ge
B
fa
ct
or
(Å
2
):
pr
ot
ei
n/
lig
an
ds
/w
at
er
28
.8
/3
5.
7/
45
.8
27
.4
/3
7.
9/
34
.2
52
.2
/4
0.
7/
48
.8
31
.0
/2
9.
5/
39
.1
30
.5
/2
8.
8/
35
.2
B
on
d
le
ng
th
s
(Å
)
0.
01
0
0.
01
0
0.
00
7
0.
00
7
0.
00
9
B
on
d
an
gl
es
(°
)
1.
28
2
1.
38
0
1.
20
9
1.
16
9
1.
32
5
M
os
tf
av
or
ed
98
.4
97
.5
97
.7
98
.6
98
.2
O
ut
lie
rs
0.
0
0.
0
0.
28
0.
0
0.
0
P
D
B
ac
ce
ss
io
n
co
de
4Z
Q
R
4Z
Q
P
4Z
Q
N
4Z
Q
O
4Z
Q
M
C
ry
st
al
liz
at
io
n
co
nd
iti
on
s
0.
1M
so
di
um
/p
ot
as
si
um
ph
os
ph
at
e
pH
6.
2,
25
%
1,
2-
pr
op
an
di
ol
,1
0%
gl
yc
er
ol
,1
6°
C
0.
1M
so
di
um
/p
ot
as
si
um
ph
os
ph
at
e
pH
6.
2,
25
%
1,
2-
pr
op
an
di
ol
,1
0%
gl
yc
er
ol
,1
6°
C
0.
3M
m
ag
ne
si
um
fo
rm
at
e,
0.
1M
T
ris
pH
8.
5,
16
°C
0.
1M
so
di
um
/p
ot
as
si
um
ph
os
ph
at
e
pH
6.
2,
25
%
1,
2-
pr
op
an
di
ol
,
10
%
gl
yc
er
ol
,1
6°
C
0.
4M
m
ag
ne
si
um
fo
rm
at
e,
0.
1M
T
ris
-
H
C
lp
H
8.
5,
20
%
su
cr
os
e,
16
°C
,
so
ak
ed
w
ith
20
0
m
M
N
A
D
A
S
U
,A
sy
m
m
et
ric
U
ni
t,
a V
al
ue
s
in
pa
re
nt
he
se
s
co
rr
es
po
nd
to
th
e
hi
gh
es
t-
re
so
lu
tio
n
sh
el
l.
b
R
m
er
g
e
=
Σ
h
kΣ
i|I
i(h
kl
)–
hI(
hk
l)i|
/Σ
h
kl
Σ
i|hI
i(h
kl
)i|
,w
he
re
I i(
hk
l)
is
th
e
in
te
ns
ity
fo
r
th
e
ith
m
ea
su
re
m
en
to
fa
n
eq
ui
va
le
nt
re
ﬂ
ec
tio
n
w
ith
in
di
ce
s
h,
k,
an
d
l.
c
R
w
o
rk
=
Σ
h
kl
||F
o
b
s|
—
|F
ca
lc
||/
Σ
h
kl
|F
o
b
s|
,w
he
re
F o
b
s
an
d
F c
al
c
ar
e
ob
se
rv
ed
an
d
ca
lc
ul
at
ed
st
ru
ct
ur
e
fa
ct
or
s,
re
sp
ec
tiv
el
y.
R
fr
ee
is
ca
lc
ul
at
ed
an
al
og
ou
sl
y
fo
r
th
e
te
st
re
ﬂ
ec
tio
ns
,w
hi
ch
w
er
e
ra
nd
om
ly
se
le
ct
ed
an
d
ex
cl
ud
ed
fr
om
th
e
re
ﬁ
ne
m
en
t.
d
Li
ga
nd
s
in
cl
ud
e
al
la
to
m
s
ex
cl
ud
in
g
pr
ot
ei
n
an
d
w
at
er
at
om
s.
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
38
97
6.
t0
04
M. tuberculosis IMP Dehydrogenase Inhibitors
PLOS ONE | DOI:10.1371/journal.pone.0138976 October 6, 2015 8 / 21
Structure of ApoMtbIMPDH2ΔCBS
The apo structure contains four polypeptide chains in the asymmetric unit (rmsds for Cα
atoms of chain A versus other three are from 0.10 to 0.12 Å). A potassium ion is bound
between subunits, interacting with six main chain carbonyls, three from the loop containing
active site C341 (G336, G338, and C341) and three from the C-terminal portion of the adjacent
subunit (E551’, S512’, and H513’). This coordination is very similar to that observed in previ-
ously reported structures [21,41,42]. A phosphate ion originating from the crystallization
buffer binds in the phosphate site of IMP, anchored by hydrogen bonding interactions with the
backbone nitrogen atoms of S339, G376, G397 and S398 and the side chains of S339 and Y421.
This interaction network is further supplemented by water-mediated contacts. Interestingly,
K454 (residue in the active site flap) occupies the position where the linker portions of P41 and
Q67 bind (see below, Fig 3A). This residue must move out of the active site when an inhibitor
binds. Thus the conformational dynamics of the active site flap may contribute to the differ-
ences in inhibitor affinities among IMPDHs from different sources.
MtbIMPDH2ΔCBS complex with XMP and NAD+
The 1.60 Å resolution crystal structure of the product/cofactor complex contains one protein
chain per asymmetric unit. Although no potassium was present in the crystallization buffer
and this ion is not found in the complex, the high quality electron density maps clearly show
that the product XMP is present in the active site (Fig 3B). This indicates that the enzyme in
the crystal is catalytically competent. XMP is in essentially the same orientation as observed
previously in IMPDH from V. cholerae (PDB id 4X3Z) [21]. The xanthine ring contacts C341,
T343, M424, G425, and E458 and also has water-mediated interactions with the main chain
nitrogen atom of G336 (Fig 3B). The phosphate group of XMP interacts with S339, G376,
G397, S398, and Y421, and the sugar moiety forms hydrogen bonds with D374. These residues
are highly conserved in all IMPDHs, with the exception of E458, which is replaced by gluta-
mine in eukaryotic IMPDHs.
As observed for VcIMPDHΔCBS•XMP•NAD+ [21], the NAD+ adenosine moiety binds in
the AB-subsite located at the subunit interface and interacts with residues from both monomers
(Fig 3C and 3D). For comparison, binding of adenosine in the AE-subsite of the hIMPDH2
complex with NAD+ and a substrate analog, CPR (hIMPDH2•CPR•NAD+; PDB code 1NFB)
is shown in Fig 3E. InMtbIMPDH2ΔCBS•XMP•NAD+ the adenine ring is in the anti-orienta-
tion with respect to the sugar ring. The adenine N3A atom contacts the side chain of N289,
whereas the N6A amine makes one hydrogen bond with the carbonyl group of A483’ and one
water-mediated contact with the side chain of E458. In addition, one side of the adenine ring
participates in van der Waals interactions involving V60’ and P61’ and the other side π/π stacks
with H286 in an edge-to-face orientation (Fig 3C). The same set of interactions is present in
VcIMPDHΔCBS•XMP•NAD+, although VcIMPDH has S256 in place of N289, L26’ instead of
V60’ and the π/π stacking with the conserved histidine residue occurs in a face-to-face orienta-
tion. The N6A amine also makes a NH2/π interaction with the side chain of Y487’ (part of the
ISMS) inMtbIMPDH2ΔCBS. This contact is not present in VcIMPDHΔCBS•XMP•NAD+
because VcIMPDH has L446’ in place Y487’ (Fig 3D). It is also important to note the adenosine
portion inMtbIMPDH2ΔCBS•XMP•NAD+ is positioned deeper into the binding pocket than
in VcIMPDHΔCBS•XMP•NAD+ and the cofactor is in a more compact orientation (C6A-C2N
distance of 9.16 Å inMtbIMPDH2ΔCBS•XMP•NAD+ versus 11.41 ± 0.11 Å in
VcIMPDHΔCBS•XMP•NAD+ [21,43]). Interestingly, the position of the adenine group in
MtbIMPDH2ΔCBS•XMP•NAD+ is more similar to the VcIMPDHΔCBS structure with NAD+
and a mixture of IMP and a covalent intermediate (VcIMPDHΔCBS•IMP•NAD+; PDB id
M. tuberculosis IMP Dehydrogenase Inhibitors
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Fig 3. Active site flap in apoMtbIMPDH2ΔCBS and cofactor orientation in
MtbIMPDH2ΔCBS•XMP•NAD+ complex. (A) Overlay of apoMtbIMPDH2ΔCBS and
MtbIMPDH2ΔCBS•IMP•P41 structures with a flap residue K454 in the apo form clashing with the linker
position of P41, indicating that these two elements occupy the same space in the active site. For
MtbIMPDH2ΔCBS•IMP•P41, only residues (lines) and P41 (sticks) are shown; color code for
MtbIMPDH2ΔCBS•IMP•P41 as in Fig 5A. For the apo structure, chains A (lime) and C (gray) are shown in a
cartoon representation and residues corresponding to these involved in inhibitor binding are shown as lines.
A prime denotes a residue from the adjacent monomer. (B) Top view of the active site showing XMP
M. tuberculosis IMP Dehydrogenase Inhibitors
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4QNE [21]). The cofactor in VcIMPDHΔCBS•IMP•NAD+ has similarly compact conforma-
tion (C6A-C2N distance of 9.42 ± 0.10 Å), with the adenine ring in an anti-conformation. Per-
haps NAD+ changes orientation during the catalytic cycle prior to its dissociation from the
active site, as suggested for VcIMPDH [21].
The interactions of the NAD+ pyrophosphate are similar to those in previously reported
cofactor structures. R108 makes two direct hydrogen bonds to O3 and O2A of the phosphate
moiety and the same phosphate group makes one direct hydrogen bond to the amido group of
A285 (part of the IMSM) and water-mediated bonds to the main chain amido and carbonyl
groups of V261. The corresponding interactions, except for R108-O3/O2A, are also found in
VcIMPDHΔCBS•XMP•NAD+ [21].
The nicotinamide ring of NAD+ stacks against the xanthine ring of XMP and the nicotin-
amide ribose is anchored via hydrogen bonds between the hydroxyl groups and the conserved
D283, as observed previously in other IMPDHs (Fig 3C). However, the orientation of the nico-
tinamide portion is opposite from that observed in other cofactor complexes. In
VcIMPDHΔCBS•XMP•NAD+, the nicotinamide ring is in the anti-conformation (Fig 3D) and
the carboxamide group makes hydrogen bonds with two conserved glycine residues [21,44].
This conformation is consistent with hydride transfer to the pro-S position of NAD+ [45,46].
However, the nicotinamide ring flips ~180° and is in a syn-conformation in
MtbIMPDH2ΔCBS•XMP•NAD+ (with χN torsion angle of 5.7°; Figs 1B and 3C). The carboxa-
mide moiety makes direct hydrogen bonds with side chains of T343, E458, and Y487’ (which is
a part of the IMSM) and a water-mediated interaction with the O1N atom of the phosphate
group and the N7A atom of adenine (Fig 3C and 3D). The carboxamide group also makes van
der Waals contacts with A285 (also a part of the IMSM). As a result of the syn-conformation,
the pro-R side of the nicotinamide ring now faces IMP with its C4N carbon aligned with the C2
of the IMP hypoxanthine ring (C4N-C2 distance of 3.28 Å).
We characterized the reaction of 2H-IMP and NAD+ to determine if the stereochemistry of
hydride transfer catalyzed byMtbIMPDHΔCBS was pro-R as suggested by the crystal structure.
As reported previously [45,46], hIMPDH2 transferred deuterium to the pro-S position of
NAD+ (S4 Fig). The deuterium also transferred to the pro-S position of NAD+ in the
MtbIMPDH2ΔCBS catalyzed reaction (S4 Fig). These observations indicate that the orientation
of NAD+ observed in the XMP complex is not competent for hydride transfer and may reflect
cofactor conformation stabilized by the IMSM.
interactions. Chain A (slate blue) and symmetry-generated adjacent chain (violet) are shown. Residues are
represented as lines. XMP (pale yellow) and NAD+ (green) are shown as sticks. (C) Side view of the active
site detailing NAD+ binding. Color code and depiction as in panel (B). For panels (B) and (C) 2mFo-DFc
electron density maps contoured at the 2 σ level for XMP (pale yellow) and 1.5 σ level for NAD+ (green) are
shown on the right. Atoms discussed in text are labeled. (D) Cofactor position in superimposed structures
MtbIMPDH2ΔCBS•XMP•NAD+ and VcIMPDHΔCBS•XMP•NAD+. Only ligands (depicted as sticks) and the
interacting residues (represented as lines) are shown. Residues are labeled according toMtbIMPDH2
numbering with VcIMPDH numbering in parentheses. Color code is as follows: for theMtb structure as in
panel (A); for the Vc structure: chain A (light orange), symmetry-generated adjacent chain (brown), NAD+
(orange), XMP and selected hydrogen bonds are omitted for clarity. (E) Overlay of the cofactor position in
MtbIMPDH2ΔCBS•XMP•NAD+ and the ternary complex of hIMPDH2 with NAD+ and substrate analog, CPR
(hIMPDH2•CPR•NAD+; PDB code 1NFB). Residues are labeled according toMtbIMPDH2 numbering with
hIMPDH2 numbering in parentheses. Color code is as follows: for theMtb structure as in panel (B); for the
human structure: chain A (light gray), symmetry-generated adjacent chain (dark gray), NAD+ (gray), CPR is
omitted for clarity. Localization of the eukaryotic AE-subsite and the bacterial AB-subsite is indicated. For all
panels (where applicable): a prime denotes a residue from the adjacent monomer. Water molecules are
shown as red spheres. Hydrogen bonds are depicted as red dashed lines.
doi:10.1371/journal.pone.0138976.g003
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Inhibitor binding
Each structureMtbIMPDH2ΔCBS•inhibitor complex contains one protein chain per asym-
metric unit with one molecule of IMP and one molecule of inhibitor bound. The active sites are
ordered and the electron densities for ligands and protein are well defined (Figs 4 and 5). The
overall structures of the inhibitor complexes are very similar, with r.m.s.d. for Cα atoms of A
chains ranging from 0.23 to 0.46 Å. The structures of complexes withMAD1 andQ67 contain
a potassium ion, as described for the apo protein. The crystallization buffer used to obtain the
IMP•P41 did not contain potassium ions (Table 4). The protein-IMP interactions are analo-
gous to those described above for XMP, as well as for previously determined structure of IMP
complexes [21,27,29,30], and will not be discussed further.
The inhibitors have modular structures consisting of two aromatic moieties connected by
different linkers (1,2,3-triazole inMAD1, urea in P41 and an amide inQ67) (Fig 1C). One aro-
matic portion of the inhibitor stacks against the hypoxanthine ring of IMP and interacts with
residues within the nicotinamide-binding subsite (the “leftside” rings, Fig 1C). The other aro-
matic moiety interacts with IMSM residue Y487’ in the AB-subsite (the “rightside” rings; Fig
1C) and the linker bends around IMSM residue A285. Specific interactions for each inhibitor
will be described below.
MtbIMPDH2ΔCBS•IMP•MAD1 complex
MAD1 is a mycophenolic acid-adenosine conjugate initially designed to target human
IMPDHs [16]. It was the first reported inhibitor ofMtbIMPDH2, although it is a much more
potent inhibitor of the human enzymes. Other mycophenolic acid-adenosine conjugates with
varying linkers did not inhibitMtbIMPDH2. The mycophenolic acid-derived moiety interacts
with IMP and forms hydrogen bonds with T343, G334 and G336 (Fig 4A). These residues are
conserved in all IMPDHs and the corresponding interactions are also present in eukaryotic
enzymes (for example, in the E-XMP•mycophenolic acid complex of Chinese hamster
IMPDH2 (PDB id 1JR1) [41]).MAD1 does not interact with E458, in contrast to the
CpIMPDH inhibitors (see below). The absence of these contacts may account for the relatively
low affinity of this compound (S9 Table). The triazole linker ofMAD1 engages in hydrogen
bonding interaction via the N3 atom with the main chain amide nitrogen atom of A285, while
the remainder of the triazole makes van der Waals contacts with R108 and T284 (Fig 4A). The
position of the adenosine portion ofMAD1 in the AB-subsite is superimposable with the posi-
tion of the adenosine moiety of NAD+ in the XMP•NAD+ complex. Consequently, interactions
with H286, N289, V60’, P61’, A483’ and Y487’ are maintained (Fig 4B). Thus,MAD1 adopts
an orientation analogous to the folded cofactor conformation that is preferred in bacterial
IMPDHs.
The divergence of the cofactor binding sites in bacterial and eukaryotic enzymes is illus-
trated by comparing the structures of theMtbIMPDH2ΔCBS•IMP•MAD1 with hIMPDH2 in
complex with anotherMAD inhibitor, C2-MAD, and ribavirin 5’-monophosphate (RVP)
(PDB id 1NF7; doi:10.2210/pdb1nf7/pdb [39]). C2-MAD is a second generation mycophenolic
adenine analogue that has a methylenebis(phosphonate) linker. The linker and mycophenolic
acid-derived portions of the inhibitors are positioned similarly in both enzymes. However, the
adenosine portion of C2-MAD rotates away from the subunit interface and binds in the AE-
subsite (Fig 4C). The C2-MAD adenine ring π/π stacks between the side chains of H253 and
F282 (hIMPDH2 numbering) located within a single monomer (Fig 4C). Thus, C2-MAD
assumes an orientation analogous to the extended NAD+ conformation preferred in eukaryotic
IMPDHs (Fig 3E). Therefore, interaction of the adenine moiety with the AE-subsite may
account for higher affinity of MAD inhibitors with eukaryotic IMPDHs.
M. tuberculosis IMP Dehydrogenase Inhibitors
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MtbIMPDH2ΔCBS •IMP•P41 complex
P41 has a urea linker connecting the 3-isoprenyl-α,α-dimethylbenzyl (left side ring) and
4-chloro-3-N,N-dimethylbenzamide [26] (right side ring; Fig 1C). The hypoxanthine ring of
IMP interacts with the sp2 center and the aromatic centroid of the left side ring (Figs 1C and
5A). Both nitrogen atoms of the urea linker form hydrogen bonds with the side chain of E458
(N1/P41—OE2/E458 and N2/P41—OE2/E458 distances of 3.27 and 3.08 Å, respectively) (Fig
5A). The interactions with E458 are observed in other inhibitor complexes and are likely to be
important for inhibitor potency [21,27,29,30]. Within the AB-subsite, the right side ring inter-
acts with the ring of Y487’ in an orientation that is midway between face-to-face and edge-to-
face geometries. The right side ring also makes contacts with H286, V60’, and P61’.
The importance of the 4-chloro substituent for antitubercular activity can be explained by
the presence of a pair of orthogonal halogen/hydrogen bonds [47,48]. The Cl atom interacts
Fig 4. Binding of mycophenolic adenine nucleotide derivative MAD1 inMtbIMPDH2ΔCBS complex.
(A)MtbIMPDH2ΔCBS•IMP•MAD1 complex. Chain A (slate) and symmetry-generated adjacent chain (violet)
are shown in a cartoon representation. Residues involved in inhibitor binding are shown as lines. A prime
denotes a residue from the adjacent monomer. Molecules of IMP (light gray) andMAD1 (yellow) are shown
as sticks. Hydrogen bonds are shown as red dashed lines. 2mFo –DFc electron density map contoured at the
1 σ level forMAD1 is shown on the right. Atoms discussed in text are labeled. (B) Overlay of
MtbIMPDH2ΔCBS•IMP•MAD1 andMtbIMPDH2ΔCBS•XMP•NAD+. Only the ligands (depicted as sticks)
and the interacting residues (represented as lines) are shown. Color code for residues as in panel (A) and Fig
3, IMP (gray),MAD1 (yellow), XMP (pale yellow), NAD+ (green). (C) Distinctive binding mode of MAD
derivatives in bacterial and human IMPDHs. Overlay ofMtbIMPDH2ΔCBS•IMP•MAD1 and
hIMPDH2•RVP•C2-MAD. Only the inhibitors (depicted as sticks) and the interacting residues (represented as
lines) are shown. Residues are labeled according toMtbIMPDH2ΔCBS numbering with hIMPDH2 numbering
in parenthesis. IMP and RVP are omitted for clarity. Color code: forMtbIMPDH2ΔCBS•IMP•MAD1 as in
panel (A); for hIMPDH2, chain A (pale green), symmetry-generated adjacent chain (dark green),C2-MAD
(teal).
doi:10.1371/journal.pone.0138976.g004
M. tuberculosis IMP Dehydrogenase Inhibitors
PLOS ONE | DOI:10.1371/journal.pone.0138976 October 6, 2015 13 / 21
Fig 5. Binding ofCpIMPDH-selective inhibitors P41 and Q67. (A)MtbIMPDH2ΔCBS•IMP•P41 complex.
(B)MtbIMPDH2ΔCBS•IMP•Q67 complex. Chain A (slate) and symmetry-generated adjacent chain (violet)
are shown in a cartoon representation. Residues are shown as lines. A prime denotes a residue from the
adjacent monomer. Molecules of IMP (light gray), P41 (magenta), andQ67 (orange) are shown as sticks.
Water molecules are depicted as red spheres. Potential hydrogen and halogen bonds are shown as red
M. tuberculosis IMP Dehydrogenase Inhibitors
PLOS ONE | DOI:10.1371/journal.pone.0138976 October 6, 2015 14 / 21
with the carbonyl of G486’ (Cl/P41 –O/G486’ distance of 3.52 Å) (Fig 5A). This carbonyl also
makes a hydrogen bond with the side chain of S57’ (O/G486’–OG/S57’ distance of 2.85 Å) at an
angle of 90° relative to the halogen bond. The halogen substituent also contacts the imidazole
ring of H286. The structure explains the diversity of carboxamide substitutions in the P com-
pounds with antitubercular activity. The carboxamide group of P41 does not participate in any
hydrogen bonds with the protein. The two methyl groups sit in a hydrophobic pocket formed
by T284, V261, A285, N289, L291 and V292. These hydrophobic interactions can explain the
higher affinity of substituted amides (Table 2, compare P34 and P67, P146 and P150).
MtbIMPDH2ΔCBS •IMP•Q67 complex
CompoundQ67 contains 2,3-dichloroaniline (left side ring) and 2-(4-pyridyl)-1,3-benzoxazole
moieties (right side ring) connected with an amide linker [27] (Fig 1C). The leftside ring inter-
acts with IMP via π/π stacking and C-X/π contacts involving the 2-chloro substituent. The
3-chloro substituent contacts the carbonyl atom of M424 and interacts with G425 (Fig 5B).
These interactions explain the prevalence of the 2,3-dichloro substituents in the set of Q com-
pounds with antitubercular activity. As in P41, the nitrogen atom of compoundQ67 amide
linker hydrogen bonds with one of the side chain oxygen atoms of E458 but the interaction for
Q67 is stronger (2.79 Å versus 3.08 and 3.27 Å for P41).
As observed for the other inhibitors, the 4-pyridyl–1,3-benzoxazole moiety ofQ67 is held in
place by interactions with H286, V60’, P61’, and Y487’ in the AB-site. In addition,Q67makes
several unique contacts: the N3 atom of the 1,3-benzoxazole group interacts with the main
chain nitrogen atom of H286 and two water molecules connect the N4 atom of the 4-pyridyl
substituent with the main chain nitrogen atom of R290 and the carbonyl oxygen atom of S57’
(Fig 5B). Similar water-mediated interactions involving the pyridyl moiety were previously
observed in the structures CpIMPDH and BaIMPDH complexes with another Q-series inhibi-
tor,Q21 [21,27]. The additional interactions of chloro substituents, the short hydrogen bond
with E458, and the network of water-mediated contacts can account for the high potency of
Q67. The structure also explains why the stereochemistry of the linker is essential. The (S)-
methyl group faces away from E458 and interacts with L455 and M430. The methyl group in
the (R) isomer is most likely oriented towards E458 and thus disrupts the crucial hydrogen
bond interaction between the amide linker and E458, making this isomer inactive.
Discussion
The structure ofMtbIMPDH2ΔCBS•XMP•NAD+ confirms our recent findings that bacterial
IMPDHs bind NAD+ in an unusual compact conformation with the AB-subsite located at the
interface between two monomers. The different locations of the AB and AE sites account for
the selectivity of the CpIMPDH inhibitors for bacterial IMPDHs. All high affinity CpIMPDH
inhibitors bind to bacterial enzymes using the AB site. In contrast, it appears that MAD inhibi-
tors bind with high affinity to human IMPDH using the AE site and with low affinity to bacte-
rial enzymes using AB site. Interestingly, the nicotinamide ring in theMtbIMPDH structure is
in a syn-conformation, which is not compatible with the pro-S hydride transfer observed in the
reaction. Similar syn NAD(H) conformations have been observed among other pro-S stereo-
specific enzymes, such as transhydrogenase [49] and UDP-galactose 4-epimerase [50]. We link
dashed lines. For panels A and B 2mFo –DFc electron density map contoured at the 1 σ level for each
inhibitor is shown on the right. Atoms discussed in text are labeled. (C) Overlay of threeMtbIMPDH2ΔCBS
inhibitor complexes. IMP is omitted for clarity. Color designations as follows: forMAD1 as in Fig 4A; for P41
andQ67 as in panels (A) and (B), respectively.
doi:10.1371/journal.pone.0138976.g005
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the ability to bind the syn-conformation with the presence of the IMSM that is essential for
inhibitor binding [10,30,31]. While hydride transfer cannot occur in the syn-conformation, it
is possible that this conformation has another regulatory role.
New antibiotics to treat tuberculosis are urgently needed. Our work identifies inhibitors of
MtbIMPDH2 with encouraging antitubercular activity. We also report the first crystal structures
of this promising antimicrobial drug target, including the apo form and complexes with XMP/
NAD+ and three structurally distinct inhibitors. These structures will greatly facilitate the fur-
ther development ofMtbIMPDH2-targeted antibiotics. OurMtbIMPDH2ΔCBS inhibitor com-
plexes provide important insights into the interactions that modulate affinity as well identify
possible locations for further inhibitor optimization for both potency and cellular accumulation.
Interactions with the hypoxanthine moiety of IMP, E458, and AB-subsite are especially impor-
tant for high affinity and selectivity. It is important to note that while the active site flap is par-
tially disordered in allMtbIMPDH2ΔCBS structures, different conformations of the flap are
observed in the apo structure and the structures of the complexes. Thus, the flap may transiently
interact with the inhibitor and these interactions may also contribute to inhibitor affinity.
Material and Methods
Materials
IMP was purchased from Acros Organics. NAD+ and NADH were purchased from Roche and
Sigma, respectively. Tris, and common chemicals were purchased from Sigma. KCl and trichlo-
roacetic acid were purchased from Fisher. CpIMPDH and BaIMPDH were purified as previ-
ously described [27,32]. The synthesis of the CpIMPDH inhibitors has been reported
previously [23–25,27–30,37]. The synthesis ofMAD1 is described in [16]. Crystallization
reagents were purchased from Hampton Research and Microlytic.
Values of cLogP and tPSA
Values of clogP and tPSA were calculated in ChemBioDraw (Cambridgesoft Inc.). The relevant
ionizations at pH 7.4 were included in the structures [37].
Cloning
The CBS domain deletion mutant (MtbIMPDH2ΔCBS) was constructed via the megaprimer
cloning method [51]. Wild typeMtbIMPDH2 clone in vector pMCSG7 [27] was used as a tem-
plate. The E126-R252 (ΔCBS) deletion primer and theMtbIMPDH2 coding sequence forward
primer were used to amplify a region ofMtbIMPDH2-pMCSG7 ranging from the residue M1
to residue V261 with 5’ LIC overhang, while replacing codons for residues E126-R252 with
codons for GG. The resulting product was used as a megaprimer in the whole plasmid synthe-
sis reaction, withMtbIMPDH2-pMCSG7 as template and a reverse primer encoding 3’ end of
MtbIMPDH2. KOD Hot Start DNA polymerase kit (EMDMillipore) was utilized in a PCR
reaction. Cycling was performed at 95° for 3 min, followed by 95° for 40 sec, 53° for 40 sec, 72°
for 1.5 min for 32 cycles. The PCR product was treated with T4 polymerase (Promega),
annealed into pMSCG7 vector, transformed into E. coli BL21(DE3) cells carrying the pMAGIC
plasmid encoding rare E. coli tRNA (Arg (AGA/AGG)) [52] and the resulting clone sequenced.
Stereochemistry of hydride transfer
[2-2H]-IMP or [2-1H]-IMP (2 mM) is mixed with NAD+ (2 mM) in assay buffer (50 mM d–11
Tris, 150 mM KCl, 1 μMDTT, pD 8.0) in D2O.MtbIMPDH (1 μM) or hIMPDH2 (1.3 μM)
was added to initiate the reaction. After 2h incubation at room temperature, the protein was
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separated from small molecules by centrifugation using Amicon centrifugal filter (Millipore,
10K cutoff), and the small molecule mixtures were directly analyzed by 400MHz 1H NMR with
water suppression using presaturation pulse.
MIC determinations
MIC is concentration that completely inhibits growth. Compounds MICs were determined as
previously described [53]. MIC values were determined in at least triplicate according to the broth
microdilution methods using compounds from DMSO stock solutions. Isoniazid was used as a
positive control and DMSOwas utilized as a negative control. IsolatedMtb cells (ATCC 27294)
were cultured to an OD 0.2–0.3 in the required medium, then diluted to deliver approximately 1 x
104 bacteria per well of a 96 well clear round-bottom plate. Plates were read after 1 week with an
inverted enlarging mirror plate reader and graded as either growth or no growth. GAST/Fe
medium (per liter) consisted of 0.3 g of Bacto Casitone (Difco), 4.0 g of dibasic potassium phos-
phate, 2.0 g of citric acid, 1.0 g of L-alanine, 1.2 g of magnesium chloride hexahydrate, 0.6 g of
potassium sulfate, 2.0 g of ammonium chloride, 1.80 ml of 10 sodium hydroxide, and 10.0 ml of
glycerol, 0.05% Tween 80 and 0.05 g of ferric ammonium citrate adjusted to pH 6.6. 7H9/glyc-
erol/glucose/BSA/Tween medium consisted of Middlebrook 7H9 broth base supplemented per
liter with 0.2% glucose, 0.2% glycerol, 0.5% BSA fraction V, 0.08%NaCl and 0.05% Tween 80.
Details of protein expression, purification, crystallization, data collection, X-ray structure
solution and refinement, steady state kinetic measurements and inhibition experiments are
listed in S1 Appendix.
Supporting Information
S1 Appendix. Details of protein expression, purification, crystallization, data collection, X-
ray structure solution and refinement, steady state kinetic measurements and inhibition
experiments.
(DOCX)
S1 Fig. Multiple sequence alignments of IMPDHs. (A) Sequence alignment of threeMtb
IMPDHs:MtbIMPDH1 (guaB1; gi: 15608980),MtbIMPDH2 (guaB2; gi: 15610547) and
MtbIMPDH3 (guaB3; gi: 444896966). Secondary structure elements derived from
MtbIMPDH2ΔCBS (PDB code 4ZQR) are depicted as arrows (representing β-strands), coils
(representing α- and 310-helices), TT (strict β-turns) and TTT (strict α-turns). The location of
CBS domain is shown as a green line. The position of catalytic Cys residue is indicated by a yel-
low rectangle. It is important to note thatMtbIMPDH3 (guaB3) does not posses the catalytic
Cys residue suggesting that this protein may not be an IMPDH enzyme. (B) Sequence align-
ment of bacterial and human IMPDHs discussed in this study. The sequences include
MtbIMPDH1 (guaB1; gi: 15608980),MtbIMPDH2 (guaB2; gi: 15610547), B. anthracis str.
Ames (gi: 30253523), V. choleraO1 biovar (gi: 15640786), human type I (gi: 217035148),
human type II (gi: 66933016) and C. parvum (gi: 323510309).MtbIMPDH3 was omitted. Sec-
ondary structure elements derived from BaIMPDH (PDB code 3TSB) are depicted as in panel
A. The location of CBS domain is shown as a green line. The position of catalytic Cys residue is
indicated by a yellow rectangle. Positions of residues involved in binding of the NAD+ adeno-
sine moiety in bacterial (AB-subsite) and eukaryotic (AE-subsite) enzymes are indicated by pur-
ple and black rectangles, respectively. In both panels identical residues are highlighted in red,
and similar residues are shown as red letters. The alignment was generated using MultiAlin
[54] and ESPript [55] programs.
(TIFF)
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S2 Fig. Comparison of the effect of inhibitors onMtbIMPDH and BaIMPDH. The line
denotes equal values of Ki,app.
(TIFF)
S3 Fig. Comparison of MIC for antitubercular activity and Ki,app for inhibition of
MtbIMPDH.
(TIFF)
S4 Fig.MtbIMPDH2ΔCBS catalyzes the transfer of hydride to the pro-S face of NAD+.
NMR spectra of IMPDH reaction mixtures after 2 h incubation of NAD+ with (A) hIMPDH2
(1.3 μM) and IMP; (B) hIMPDH2 (1.3 μM) and [2-2H]-IMP; (C)MtbIMPDH2ΔCBS (1 μM)
and IMP; (D)MtbIMPDH2ΔCBS (1 μM) and [2-2H]-IMP. The peaks assigned to protons on
C–4 of NADH nicotinamide ring are shown.
(TIFF)
S1 Table. Structures of inactive A series amide derivatives. All values are the average of at
least two determinations unless otherwise noted. a. Data from [24]. b. Data from [23]. c. Data
from [37]. d. Single determination.
(DOCX)
S2 Table. Structures of inactive A series triazole derivatives. a. Data from [24]. b. Data from
[37]. c. Single determination.
(DOCX)
S3 Table. SAR of enzyme inhibition for C series benzimidazole derivatives. n.d. = not deter-
mined. a. CpIMPDH data from [30]. b. Data from [25]. c. BaIMPDH data from [37]. c. Single
determination.
(DOCX)
S4 Table. Structures of inactive D series phthalazinone derivatives. n.d. = not determined. a.
Data from [28]. b. Data from [37]. c. Single determination.
(DOCX)
S5 Table. Structures of inactive P compounds. n.d. = not determined. a. Data from [26]. b.
Data from [37].
(DOCX)
S6 Table. P series: SAR of enzyme inhibition for the isopropyl and urea group. n.d. = not
determined. a. Data from [26]. b. Data from [37].
(DOCX)
S7 Table. Structures of inactive Q compounds. n.d. = not determined. n.d. = not determined
a. Data from [27]. b. Data from [37].
(DOCX)
S8 Table. CpIMPDH inhibitors with antitubercular activity: comparison of enzyme inhibi-
tion. n.d. = not determined. a. Data from [26]. b. Data from [27]. c. Data from [37]. d. Single
determination. e. Two determinations.
(DOCX)
S9 Table. Inhibition ofMtbIMPDH2ΔCBS.  Indicates tight binding conditions. C, competi-
tive inhibition; UC, uncompetitive inhibition, NC, noncompetitive inhibition.
(DOCX)
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